© The Author 2005. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Correspondence |
Long-term cost-efficacy of rituximab in immune thrombocytopenic purpura
| The first 10% of the full text of this article appears below. |
Sir,
Prior to 1981, the only effective treatments for increasing platelet count in immune thrombocytopenic purpura (ITP) were corticosteroids and splenectomy. More recently, intravenous immunoglobulin (IVIg) and Rh immunoglobulin (IV RhIg) have demonstrated efficacy. Other treatments, including danazol, azathioprine, cyclophosphamide, vinca alkaloids and cyclosporin A, are supported by small and mostly uncontrolled clinical trials.
When conventional therapy fails,
Servicio de Medicina Interna Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain email: mibh-jperez@hcu-lblesa.es
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
D. J. Nugent Immune Thrombocytopenic Purpura of Childhood Hematology, January 1, 2006; 2006(1): 97 - 103. [Abstract] [Full Text] [PDF] |
||||
